Showing Form 4 filings for ACAD
Pre-configured institutional-grade criteria for instant high-conviction screening
Multiple insiders buying stock within the last 30 days
Direct open-market purchases by Chief Executive Officers
Financial chiefs and top corporate officers accumulating shares
Institutional-scale insider purchases of $1,000,000 or greater
Insiders increasing their overall equity ownership by over 20%
High-value executive divestments by CEOs and CFOs over $1M
Acadia Pharmaceuticals Inc
Price
$20.88
Shares
3,321
Ownership
71,322
Value/Share
Schneyer Mark C.
EVP, CFO
Unknown
Industry